

## Press Release

**Media contact**

Leif Heussen  
T +49 6172 608-4030  
leif.heussen@fresenius.com

**Contact for analysts  
and investors**

Dr. Dominik Heger  
T +49 6172 609-2601  
dominik.heger@fmc-ag.com

November 1, 2023

[www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com)

### **Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter**

- Continued solid organic growth in Care Enablement and Care Delivery including sequentially stable same market treatment growth in the U.S.
- Successful execution on turnaround plan driving productivity improvements in Care Delivery and pricing in Care Enablement
- FME25 transformation savings fully on track
- Continued execution on portfolio optimization strategy
- FY 2023 earnings outlook raised

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: *"Our unwavering focus on executing against our strategic plan and the successful implementation of turnaround measures to date, continue to translate into improved operating performance. Notably in the third quarter, we continued to unlock sustainable savings with our FME25 program, further improved our labor productivity and continued to execute on our portfolio optimization plan. Given our improving performance for the first nine months of the year and solid expectations for the remainder of the year, we confidently upgrade our full year earnings outlook."*

## **Key figures (IFRS, unaudited)**

	Q3 2023	Q3 2022	Growth	Growth	9M 2023	9M 2022	Growth	Growth
	EUR m	EUR m	yoy	yoy, cc	EUR m	EUR m	yoy	yoy, cc
<b>Revenue</b>	<b>4,936</b>	<b>5,096</b>	<b>-3%</b>	<b>+7%</b>	<b>14,466</b>	<b>14,401</b>	<b>0%</b>	<b>+5%</b>
<b>Operating income</b>	<b>324</b>	<b>472</b>	<b>-31%</b>	<b>-28%</b>	<b>942</b>	<b>1,160</b>	<b>-19%</b>	<b>-18%</b>
excl. special items and PRF <sup>1</sup>	431	377	+14%	+20%	1,186	1,052	+13%	+14%
<b>Net income<sup>2</sup></b>	<b>84</b>	<b>230</b>	<b>-63%</b>	<b>-61%</b>	<b>311</b>	<b>535</b>	<b>-42%</b>	<b>-41%</b>
excl. special items and PRF <sup>1</sup>	168	168	0%	+5%	497	481	+3%	+5%
<b>Basic EPS (EUR)</b>	<b>0.29</b>	<b>0.78</b>	<b>-63%</b>	<b>-61%</b>	<b>1.06</b>	<b>1.82</b>	<b>-42%</b>	<b>-41%</b>
excl. special items and PRF <sup>1</sup>	0.57	0.57	0%	+5%	1.69	1.64	+3%	+5%

yoy = year-on-year, cc = at constant currency, EPS = earnings per share

## **Successful execution against the strategic plan**

Fresenius Medical Care has continuously advanced its structural change. After implementing the new operating model along with the corresponding new financial reporting, the simplification of the governance structure through a legal form conversion remains on track to be completed by 1 December 2023.

Fresenius Medical Care continues to successfully execute on its operational efficiency and turnaround plans. In the third quarter, the FME25 transformation program delivered EUR 97 million of savings, resulting in EUR 232 million for the first nine months of the year. The Company is fully on track to achieve sustainable savings of EUR 250 to 300 million by year end 2023 and EUR 650 million by year end 2025.

Moreover, Fresenius Medical Care is executing its portfolio optimization plan to exit non-core and dilutive assets. In the third quarter, the Company entered into an agreement to sell National Cardiovascular Partners (NCP) with 21 facilities providing outpatient cardiac catheterization and vascular laboratory services, which are included in the U.S. Care Delivery business, in connection with its Legacy Portfolio Optimization program.

<sup>1</sup> For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Türkiye, the Humacyte investment remeasurement and the net gain related to InterWell Health. Additionally, the FY 2022 basis for the 2023 outlook was adjusted for U.S. Provider Relief Funding. For FY 2023, special items include costs related to the FME25 program, the Humacyte investment remeasurement, the costs associated with the legal form conversion and effects from legacy portfolio optimization. For further details please see the reconciliation attached to the Press Release.

<sup>2</sup> Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

In line with the Company's disciplined financial policy, Fresenius Medical Care has already refinanced a bond of EUR 650 million, maturing in November 2023. The Company is using a mix of long-term bank financing at very attractive financing conditions as well as cash and short-term debt. Upcoming extraordinary cash inflows will enable the Company to further delever.

## Revenue development supported by solid organic growth

**Revenue** decreased by 3% to EUR 4,936 million in the third quarter (+7% at constant currency, +7% organic).

**Care Delivery** revenue decreased by 4% to EUR 3,974 million (+6% at constant currency, +7% organic).

In Care Delivery U.S., revenue declined by 3% (+4% at constant currency, +5% organic). A negative exchange rate effect and a decrease in dialysis days was partially offset by organic growth, which was supported by a favorable impact from the value-based care business, reimbursement rate increases and a favorable payor mix. The annualization effect of COVID-19-related excess mortality in the late-stage CKD (Chronic Kidney Disease) and ESRD (End-Stage Renal Disease) population continues to weigh on same market treatment growth (-0.4%). Adjusted for the exit from less profitable acute care contracts same market treatment growth was at +0.2%.

In Care Delivery International, revenue declined by 7% (+14% at constant currency, +16% organic). A negative exchange rate effect and the impact of closed or sold clinics was partially offset by organic growth, which was driven by a significant effect of hyperinflation in various markets. Despite the annualization effect of COVID-19-related excess mortality, same market treatment growth was positive at 1.6%.

**Care Enablement** revenue declined by 3% to EUR 1,330 million (+5% at constant currency, +5% organic). The negative exchange rate effects have been partly offset by higher sales of in-center disposables, machines for chronic treatment and home hemodialysis products as well as higher average sales prices.

Within **Inter-segment eliminations**, revenue for products transferred between the operating segments at fair market value declined by 10% to EUR 368 million (-1% at constant currency).<sup>3</sup>

---

<sup>3</sup> The Company transfers products between segments at fair market value. The associated internal revenues and expenses and any remaining internally generated profit or loss for the product transfers are recorded within the operating segments initially, are eliminated upon consolidation and are included within "Inter-segment eliminations".

In the first nine months, revenue was stable at EUR 14,466 million (+5% at constant currency, +5% organic). Care Delivery revenue was stable at EUR 11,602 million (+4% at constant currency, +5% organic), with stable revenue for Care Delivery U.S. (+2% at constant currency, +3% organic), and a revenue decline of 1% for Care Delivery International (+13% at constant currency, +14% organic). Care Enablement revenue was stable at EUR 3,965 million (+5% at constant currency, +5% organic). Inter-segment eliminations declined by 5% and amounted to EUR 1,101 million (stable at constant currency).

## **Earnings development driven by productivity improvements and FME25 savings**

**Operating income** decreased by 31% to EUR 324 million (-28% at constant currency), resulting in a margin of 6.6% (Q3 2022: 9.3%). Operating income excluding special items and U.S. Provider Relief Funding (PRF)<sup>1</sup> increased by 14% to EUR 431 million (+20% at constant currency), resulting in a margin of 8.7% (Q3 2022: 7.4%).

Operating income in **Care Delivery** decreased by 34% to EUR 332 million (-29% at constant currency), resulting in a margin of 8.4% (Q3 2022: 12.1%). Operating income excluding special items and PRF<sup>1</sup> increased by 11% to EUR 410 million (+17% at constant currency), resulting in a margin of 10.3% (Q3 2022: 9.0%). This was mainly driven by business growth, savings from the FME25 program and lower personnel expenses resulting from improved productivity. The operating income development was negatively impacted by lower income attributable to a non-recurring consent payment for certain pharmaceuticals, inflationary cost increases as well as by foreign currency translation.

Operating income in **Care Enablement** amounted to EUR -1 million (Q3 2022: EUR -26 million), resulting in a margin of -0.1% (Q3 2022: -1.9%). Operating income excluding special items increased by 197% to EUR 22 million (+217% at constant currency), resulting in a margin of 1.7% (Q3 2022: 0.5%). The improvement compared to the previous year's quarter was mainly driven by increased volumes, improved pricing and savings from the FME25 program. These effects were partially offset by inflationary cost increases and negative foreign currency transaction effects.

Operating income for **Corporate** amounted to EUR -8 million (Q3 2022: EUR -7 million). Excluding special items, operating income amounted to EUR -2 million (Q3 2022: EUR -6 million).

In the first nine months, operating income decreased by 19% to EUR 942 million (-18% at constant currency), resulting in a margin of 6.5% (9M 2022: 8.1%). Excluding special items and PRF<sup>1</sup>, operating income increased by 13% to EUR 1,186 million (+14% at constant currency), resulting in a margin of 8.2% (9M 2022: 7.3%). In Care Delivery, operating income declined by 19% to EUR 1,001 million (-18% at constant currency),

resulting in a margin of 8.6% (9M 2022: 10.6%). In Care Enablement, operating income decreased to EUR -24 million (9M 2022: EUR 33 million), resulting in a margin of -0.6% (9M 2022: 0.8%). Operating income for Corporate amounted to EUR -23 million (9M 2022: EUR -101 million).

**Net income<sup>2</sup>** decreased by 63% to EUR 84 million (-61% at constant currency). Excluding special items and PRF<sup>1</sup>, net income<sup>2</sup> remained stable at EUR 168 million (+5% at constant currency).

In the first nine months, net income<sup>2</sup> declined by 42% to EUR 311 million (-41% at constant currency). Excluding special items and PRF<sup>1</sup>, net income<sup>2</sup> increased by 3% to EUR 497 million (+5% at constant currency).

**Basic earnings per share (EPS)** decreased by 63% to EUR 0.29 (-61% at constant currency). EPS excluding special items and PRF<sup>1</sup> remained stable at EUR 0.57 (+5% at constant currency).

In the first nine months, EPS declined by 42% to EUR 1.06 (-41% at constant currency). Excluding special items and PRF<sup>1</sup>, EPS increased by 3% to EUR 1.69 (+5% at constant currency).

## Strong cash flow development

In the third quarter, Fresenius Medical Care generated EUR 760 million of **operating cash flow** (Q3 2022: EUR 658 million), resulting in a margin of 15.4% (Q3 2022: 12.9%). The increase in net cash provided by operating activities is the result of the change in certain working capital items, in particular due to the recoupment of advanced payments during 2022, which had been received under the U. S. Medicare Accelerated and Advance Payment Program in 2020.

In the first nine months, operating cashflow amounted to EUR 1,910 million (9M 2022: EUR 1,568 million), resulting in a margin of 13.2% (9M 2022: 10.9%).

**Free cash flow**<sup>4</sup> amounted to EUR 626 million in the third quarter (Q3 2022: EUR 501 million), resulting in a margin of 12.7% (Q3 2022: 9.8%). In the first nine months, Fresenius Medical Care generated free cash flow of EUR 1,480 million (9M 2022: EUR 1,082 million), resulting in a margin of 10.2% (9M 2022: 7.5%).

## Outlook

The Company continues to expect for 2023 revenue to grow at a low to mid-single digit percentage rate (2022 basis: EUR 19,398 million).

Based on the earnings development for the first nine months of the year and solid business expectations for the remainder of the year, Fresenius Medical Care raises its earnings outlook for 2023. The Company now expects operating income to grow at a low-single digit percentage rate (2022 basis: EUR 1,540 million; previous target: remain flat or decline by up to a low-single digit percentage rate)<sup>5</sup>.

The Company's target to achieve an operating income margin of 10 to 14% by 2025 remains unchanged.

---

<sup>4</sup> Net cash provided by / used in operating activities, after capital expenditures, before acquisitions, investments, and dividends

<sup>5</sup> Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special items. Special items will be provided as separate KPI ("Revenue excluding special items", "Operating income excluding special items") to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items. For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Türkiye, the Humacyte investment remeasurement, and the net gain related to InterWell Health. Additionally, the basis (FY 2022) for the 2023 outlook was adjusted for Provider Relief Funding. For FY 2023, special items include costs related to the FME25 program, the Humacyte investment remeasurement, the costs associated with the legal form conversion and effects from legacy portfolio optimization. For further details please see the reconciliation attached to the Press Release.

## Patients, clinics and employees

As of September 30, 2023, Fresenius Medical Care treated 341,793 **patients** in 4,014 dialysis **clinics** worldwide and had 123,106 **employees** (headcount) globally, compared to 130,295 employees as of September 30, 2022.

## Conference call

Fresenius Medical Care will host a conference call to discuss the results of the third quarter on November 2, 2023 at 3:30 p.m. CET / 10:30 a.m. EDT. Details will be available on the Fresenius Medical Care website in the "[Investors](#)" section. A replay will be available shortly after the call.

*Please refer to our statement of earnings included at the end of this news and to the attachments as separate PDF files for a complete overview of the results of the third quarter and first nine months of 2023. Our 6-K disclosure provides more details.*

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,014 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 342,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at [www.freseniusmedicalcare.com](http://www.freseniusmedicalcare.com).

### Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Implementation of measures as presented herein may be subject to information and consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.

**Statement of earnings**

in € million, except share data, unaudited

Three months ended September 30,

	<b>2023</b>	<b>2022</b>	Change	Change at cc
<b>Revenue</b>	<b>4,936</b>	<b>5,096</b>	<b>-3.1%</b>	<b>6.6%</b>
Costs of revenue	3,707	3,853	-3.8%	6.4%
Selling, general and administrative expenses	794	817	-2.9%	4.6%
Research and development expenses	53	61	-13.7%	-10.8%
Income from equity method investees	(23)	(17)	29.7%	30.5%
Other operating income	(65)	(158)	-78.8%	-74.5%
Other operating expense	146	215	-32.6%	-14.4%
Remeasurement Gain from InterWell Health	—	(147)		
<b>Operating income</b>	<b>324</b>	<b>472</b>	<b>-31.3%</b>	<b>-27.8%</b>
Operating income excl. special items and PRF	431	377	14.2%	19.7%
Interest expense, net	89	76	16.0%	19.4%
<b>Income before taxes</b>	<b>235</b>	<b>396</b>	<b>-40.4%</b>	<b>-36.9%</b>
Income tax expense	88	112	-21.2%	-17.8%
<b>Net income</b>	<b>147</b>	<b>284</b>	<b>-48.0%</b>	<b>-44.5%</b>
Net income attributable to noncontrolling interests	63	54	18.7%	26.8%
<b>Net income<sup>1</sup></b>	<b>84</b>	<b>230</b>	<b>-63.3%</b>	<b>-60.9%</b>
Net income <sup>1</sup> excl. special items and PRF	168	168	-0.2%	4.8%
Weighted average number of shares	293,413,449	293,413,449		
<b>Basic earnings per share</b>	<b>€0.29</b>	<b>€0.78</b>	<b>-63.3%</b>	<b>-60.9%</b>
Basic earnings per share excl. special items and PRF	€0.57	€0.57	-0.2%	4.8%
<b>In percent of revenue</b>				
<b>Operating income margin</b>	<b>6.6 %</b>	<b>9.3%</b>		
Operating income margin excl. special items and PRF	8.7%	7.4%		

<sup>1</sup> Attributable to shareholders of FMC AG & Co. KGaA.

For a reconciliation of special items, please refer to the table at the end of the press release.



**Statement of earnings**

in € million, except share data, unaudited

Nine months ended September 30,

	2023	2022	Change	Change at cc
<b>Revenue</b>	<b>14,466</b>	<b>14,401</b>	<b>0.4%</b>	<b>4.9%</b>
Costs of revenue	10,890	10,738	1.4%	6.1%
Selling, general and administrative expenses	2,351	2,365	-0.6%	2.4%
Research and development expenses	166	167	-0.4%	0.5%
Income from equity method investees	(98)	(47)	108.1%	108.2%
Other operating income	(258)	(397)	-52.6%	-44.4%
Other operating expense	473	562	-16.0%	1.2%
Remeasurement Gain from InterWell Health	—	(147)		
<b>Operating income</b>	<b>942</b>	<b>1,160</b>	<b>-18.8%</b>	<b>-18.0%</b>
Operating income excl. special items and PRF	1,186	1,052	12.8%	14.1%
Interest expense, net	252	217	16.0%	16.2%
<b>Income before taxes</b>	<b>690</b>	<b>943</b>	<b>-26.8%</b>	<b>-25.9%</b>
Income tax expense	214	242	-11.5%	-10.5%
<b>Net income</b>	<b>476</b>	<b>701</b>	<b>-32.1%</b>	<b>-31.2%</b>
Net income attributable to noncontrolling interests	165	166	-0.8%	1.0%
<b>Net income<sup>1</sup></b>	<b>311</b>	<b>535</b>	<b>-41.8%</b>	<b>-41.2%</b>
Net income <sup>1</sup> excl. special items and PRF	497	481	3.3%	4.7%
Weighted average number of shares	293,413,449	293,190,145		
<b>Basic earnings per share</b>	<b>€1.06</b>	<b>€1.82</b>	<b>-41.9%</b>	<b>-41.3%</b>
Basic earnings per share excl. special items and PRF	€1.69	€1.64	3.2%	4.6%
<b>In percent of revenue</b>				
<b>Operating income margin</b>	<b>6.5%</b>	<b>8.1%</b>		
Operating income margin excl. special items and PRF	8.2%	7.3%		

<sup>1</sup> Attributable to shareholders of FMC AG & Co. KGaA.

For a reconciliation of special items, please refer to the table at the end of the press release.

**Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting Standards financial measures for comparability with the Company's outlook**  
in € million, unaudited

Three months ended September 30,    Nine months ended September 30,  
**2023                          2022                          2023                          2022**

**Operating performance excl. special items**

These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items.

	<b>2023</b>	<b>2022</b>	<b>2023</b>	<b>2022</b>
<b>Revenue</b>	<b>4,936</b>	<b>5,096</b>	<b>14,466</b>	<b>14,401</b>
<b>Operating income</b>	<b>324</b>	<b>472</b>	<b>942</b>	<b>1,160</b>
Special items:				
FME25 Program	49	53	100	109
Legal Form Conversion Costs	6	—	13	—
Legacy Portfolio Optimization <sup>1</sup>	53	—	147	—
Humacyte Investment Remeasurement	(1)	1	(16)	79
Net Gain Related to InterWell Health <sup>2</sup>	—	(56)	—	(56)
Ukraine War <sup>3</sup>	—	0	—	24
Hyperinflation in Turkiye	—	0	—	6
Provider Relief Funding (PRF)	—	(93)	—	(270)
Sum of special items and PRF	<u>107</u>	<u>(95)</u>	<u>244</u>	<u>(108)</u>
Operating income excl. special items and PRF	<b>431</b>	<b>377</b>	<b>1,186</b>	<b>1,052</b>
<b>Net income<sup>4</sup></b>	<b>84</b>	<b>230</b>	<b>311</b>	<b>535</b>
Special items:				
FME25 Program	31	38	71	78
Legal Form Conversion Costs	4	—	9	—
Legacy Portfolio Optimization <sup>1</sup>	50	—	118	—
Humacyte Investment Remeasurement	(1)	1	(12)	58
Net Gain Related to InterWell Health <sup>2</sup>	—	(38)	—	(38)
Ukraine War <sup>3</sup>	—	0	—	21
Hyperinflation in Turkiye	—	0	—	6
Provider Relief Funding	—	(63)	—	(179)
Sum of special items and PRF	<u>84</u>	<u>(62)</u>	<u>186</u>	<u>(54)</u>
Net income <sup>4</sup> excl. special items and PRF	<b>168</b>	<b>168</b>	<b>497</b>	<b>481</b>

<sup>1</sup> Costs mainly comprise the derecognition of capitalized development costs and the impairment of intangible assets (licenses and distribution rights) as well as termination costs (including certain contractual obligation expenses) related to a dialysis cyclor development program which was discontinued in the first quarter of 2023 and other expenses related to divestitures agreed upon in the second and third quarters of 2023.

<sup>2</sup> Remeasurement gain of the investment, prior to the transaction, in InterWell Health LLC, the impairment of certain long-lived assets belonging to Acumen Physician Solutions, LLC which was transferred to InterWell Health as part of the transaction and certain transaction-related costs.

<sup>3</sup> Bad debt expense in Russia and Ukraine and accruals for certain risks associated with allowances on inventories related to the Ukraine War.

<sup>4</sup> Attributable to shareholders of FMC AG & Co. KGaA